This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Abacus Diagnostica Oy. Active years: 2012.
Company Filing History:
Years Active: 2012
Title: The Innovative Contributions of Piia Von Lode
Introduction
Piia Von Lode is a notable inventor based in Paattinen, Finland. She has made significant contributions to the field of molecular diagnostics, particularly through her innovative methods for detecting target polynucleotides in samples. Her work is essential for advancing diagnostic techniques and improving the accuracy of genetic testing.
Latest Patents
Piia Von Lode holds a patent for a method titled "Method for detection of presence of target polynucleotide in samples." This method involves providing a mixture of the sample and a target binding agent, followed by measuring a signal from the mixture. The target binding agent can exist in two positions: one where it is not bound to the target polynucleotide and another where it is bound. The intensity of the signal is dependent on the proportion of the target binding agent in these two positions. This method is particularly suitable for detecting PCR products using a homogeneous detection approach. She has 1 patent to her name.
Career Highlights
Piia is currently associated with Abacus Diagnostica Oy, a company that specializes in molecular diagnostics. Her role at the company allows her to apply her innovative ideas and contribute to the development of advanced diagnostic solutions.
Collaborations
Throughout her career, Piia has collaborated with talented individuals such as Anniina Syrjälä and Virve Hagren. These collaborations have fostered a creative environment that encourages the exchange of ideas and enhances the development of innovative solutions in the field.
Conclusion
Piia Von Lode's contributions to the field of molecular diagnostics exemplify the impact of innovation in healthcare. Her patented method for detecting target polynucleotides showcases her commitment to advancing diagnostic techniques. Through her work, she continues to influence the future of genetic testing and diagnostics.